PB2342 SAFETY AND EFFICACY OF 4 CYCLES OF BRENTUXIMAB VEDOTIN AS CONSOLIDATION AFTER AUTOLOGOUS PERIPHERAL STEM CELL TRANSPLANTION IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA

Abstract

Background: Brentuximab Vedotin (BV) is a chimeric anti CD30 IgG1 antibody, conjugated to synthetic antitubulin momomethyl auristatin. BV is approved for the treatment of classical Hodgkin lymphoma (HL) in relapse either after autologous stem cell transplantation (ASCT) or after two lines of combination chemotherapy in transplant ineligible patients. The AETHERA trial revealed increased PFS when BV is used as maintenance therapy for 16 cycles in high risk patients after ASCT. However, this schedule is associated with a high cost and significant toxicity particularly in term of peripheral neuropathy. Aims: Our primary objective is to assess the efficacy of 4 cycles Brentuximab as consolidation therapy after ASCT for relapsed/refractory (R/R) HL. Secondary objectives include side effects, progression free survival (PFS), and overall Survival (OS). Methods: Patients and Methods: This is a retrospective single center analysis approved by the IRB of the American University of Beirut Medical Center. We included in this study consecutive patients with R/R HL who underwent ASCT between 2014 and 2017, and received BV consolidation post-ASCT. Results: We identified 18 consecutive adult patients with R/R HL treated with BV 1.8 mg/kg IV every 4 weeks as consolidation therapy after ASCT. The indications for BV consolidation was primary refractory disease in 9 patients (50%), early relapse in 8 patients (44%) (after a median time of 10 months; range, 3-11) and extranodal involvement in one patient (6%). The median number of lines of therapy pre-ASCT was 3 (range, 2-5). The median time to BV initiation post-ASCT was 68 days (range, 35-188). Patients received a median of 4 cycles (range, 1-5) of BV post-ASCT. After a median follow up of 32 months (range, 20-53), three (17%) patients relapsed after ASCT. The median time to relapse was 6 months (range, 4-8). Median PFS and OS were not reached. We did not observe any significant toxicities during or after therapy. Summary/Conclusion: Conclusion: 4 cycles of BV consolidation after ASCT seem to be safe and effective in preventing relapse, however our findings need to be confirmed with larger prospective studies.